Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to 0.09%.

  • Gyre Therapeutics' Return on Capital Employed rose 7900.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 7900.0%. This contributed to the annual value of 0.16% for FY2024, which is 9900.0% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Return on Capital Employed stood at 0.09%, which was up 7900.0% from 0.08% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Return on Capital Employed high stood at 0.68% for Q1 2023, and its period low was 2.3% during Q1 2022.
  • Over the past 5 years, Gyre Therapeutics' median Return on Capital Employed value was 0.64% (recorded in 2024), while the average stood at 0.53%.
  • Within the past 5 years, the most significant YoY rise in Gyre Therapeutics' Return on Capital Employed was 29900bps (2023), while the steepest drop was -17600bps (2023).
  • Over the past 5 years, Gyre Therapeutics' Return on Capital Employed (Quarter) stood at 1.66% in 2021, then soared by 112bps to 0.2% in 2022, then tumbled by -872bps to 1.56% in 2023, then soared by 110bps to 0.15% in 2024, then tumbled by -44bps to 0.09% in 2025.
  • Its last three reported values are 0.09% in Q3 2025, 0.08% for Q2 2025, and 0.1% during Q1 2025.